D
Dan H. Barouch
Researcher at Beth Israel Deaconess Medical Center
Publications - 525
Citations - 48541
Dan H. Barouch is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Immune system & Vaccination. The author has an hindex of 92, co-authored 447 publications receiving 35945 citations. Previous affiliations of Dan H. Barouch include Massachusetts Institute of Technology & Beth Israel Deaconess Hospital.
Papers
More filters
Journal ArticleDOI
Phenotypic Analysis of Antigen-Specific T Lymphocytes
John D. Altman,Paul Moss,Philip J. R. Goulder,Dan H. Barouch,Michael G. McHeyzer-Williams,John I. Bell,Andrew J. McMichael,Mark M. Davis +7 more
TL;DR: Tetramers of human lymphocyte antigen A2 that were complexed with two different human immunodeficiency virus (HIV)-derived peptides or with a peptide derived from influenza A matrix protein bound to peptide-specific cytotoxic T cells in vitro and to T cells from the blood of HIV-infected individuals and correlated well with cytotoxicity assays.
Journal ArticleDOI
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.
Journal ArticleDOI
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald C. Sadoff,Glenda Gray,An Vandebosch,Vicky Cardenas,Georgi Shukarev,Beatriz Grinsztejn,Paul A. Goepfert,Carla Truyers,Hein Fennema,Bart Spiessens,Kim Offergeld,Gert Scheper,Kimberly L Taylor,Merlin L. Robb,John J. Treanor,Dan H. Barouch,Jeffrey J. Stoddard,Martin Ryser,Mary A. Marovich,Kathleen M. Neuzil,Lawrence Corey,Nancy Cauwenberghs,Tamzin Tanner,Karin Hardt,Javier Ruiz-Guiñazú,Mathieu Le Gars,Hanneke Schuitemaker,Johan Van Hoof,Frank Struyf,Macaya Douoguih +29 more
TL;DR: A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial.
Journal ArticleDOI
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Jingyou Yu,Lisa H. Tostanoski,Lauren Peter,Noe B. Mercado,Katherine McMahan,Shant H. Mahrokhian,Joseph P. Nkolola,Jinyan Liu,Zhenfeng Li,Abishek Chandrashekar,David R. Martinez,Carolin Loos,Caroline Atyeo,Stephanie Fischinger,John S. Burke,Matthew D. Slein,Yuezhou Chen,Adam Zuiani,Felipe J.N. Lelis,Meghan Travers,Shaghayegh Habibi,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Renita Brown,Anthony Cook,Brad Finneyfrock,Alan Dodson,Elyse Teow,Jason Velasco,Roland Zahn,Frank Wegmann,Esther A. Bondzie,Gabriel Dagotto,Makda S. Gebre,Xuan He,Catherine Jacob-Dolan,Marinela Kirilova,Nicole Kordana,Zijin Lin,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,John D. Ventura,Huahua Wan,Yongfei Cai,Bing Chen,Aaron G. Schmidt,Duane R. Wesemann,Ralph S. Baric,Galit Alter,Hanne Andersen,Mark G. Lewis,Dan H. Barouch,Dan H. Barouch +54 more
TL;DR: Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.
Journal ArticleDOI
Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination
Dan H. Barouch,Sampa Santra,Jörn E. Schmitz,Marcelo J. Kuroda,Tong-Ming Fu,Wendeline Wagner,Miroslawa Bilska,Abie Craiu,Xin Xiao Zheng,Georgia R. Krivulka,Kristin Beaudry,Michelle A. Lifton,Christine E. Nickerson,Wendy L. Trigona,Kara Punt,Dan C. Freed,Liming Guan,Sheri Dubey,Danilo R. Casimiro,Adam J. Simon,Mary-Ellen Davies,Michael Chastain,Terry B. Strom,Rebecca Gelman,David C. Montefiori,Mark G. Lewis,Emilio A. Emini,John W. Shiver,Norman L. Letvin +28 more
TL;DR: The protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys is reported, with no evidence of clinical disease or mortality after challenge.